As of April 2026, global health agencies including the ECDC and WHO report no SARS-CoV-2 strains currently meeting formal variant-of-concern criteria, with ongoing surveillance focused on Omicron sublineages such as XFG and BA.3.2. The latter, nicknamed “Cicada,” carries dozens of spike mutations and has spread to over 20 countries since late 2024, yet it accounts for under 1 percent of U.S. sequences and has not driven measurable rises in transmissibility, severity, or hospitalizations. Stable low case volumes and routine vaccine updates against dominant lineages reinforce trader consensus that incremental evolution, rather than a sudden public-health threat, is the prevailing pattern. This evidence supports the strong market tilt toward no new designation before 2027.